Global Leukemia Antibodies Market, Drug Sales and Clinical Trials Insight 2028

  • No. of Pages: 300
  • Publish Date: May-2022
  • Category: Pharmaceutical and Healthcare
Electronic Access - Single User License
CD-ROM Mail Delivery
Hard Copy Mail Delivery
Electronic Access - Multi-User License

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Leukemia Cancer Antibodies Market, Drug Sales and Clinical Trials Insight 2028 Report Highlights:


  • Leukemia  Cancer Antibodies Market Global and Regional Outlook
  • Global Leukemia  Cancer Antibodies Market Opportunity > USD 4 Billion
  • Global and Regional Sales Analysis
  • Leukemia  Cancer Antibody Drug Conjugates , Monoclonal Antibodies, Bispecific Antibodies Insight
  • Pricing, Dosage, Patent Insight On Approved Leukemia  Cancer Antibodies
  • Comprehensive Insight On More Than  100 Leukemia  Cancer Antibodies in Clinical Trials
  • Leukemia  Cancer Antibodies in Clinical Trials Insight By Phase, Company, Orphan Designation


Antibody therapeutics represents one of the most promising classes of immunotherapy which is designed to harness the potential of immune system in the targeting of cancer. These therapeutics have shown to significantly improve the survival rate in wide range of cancers include leukemia and its various subtypes. Based on the rapidity of cell proliferation, leukemia can be classified as acute or chronic, and myeloid or lymphoid based on the originator cell. The dominant subtypes of leukemia are acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) which have shown increasing prevalence in the global population.


The genomic analysis has demonstrated high expression of CD20 and CD33 on the leukemic cells. Therefore, these receptors have emerged as promising druggable targets for the immunotherapeutic approaches. At present, a cocktail of monoclonal antibodies and antibody drug conjugates directed towards these receptors have entered the global market. Moreover, bispecific antibody targeting CD19 as well as CD3 has also been approved for the management of acute lymphoblastic leukemia. The encouraging response of this therapeutics has propelled the further research and development activities in this domain. Presently, more than 100 clinical trials are ongoing in global leukemia antibody therapeutics market.


US is currently holding the maximum number of clinical trials in the market which is mainly attributed to the presence of major key players in the region associated with their huge investments in this segment. For instance, Immunogen has developed IMGN632, which is a CD123 targeted antibody drug conjugate in clinical development for the management of acute myeloid leukemia. Researchers are evaluating the role of investigational drug in combination with Vidaza (azacitidine) and Venclextaandreg; (venetoclax) (triplet) in patients with relapsed/ refractory (R/R) acute myeloid leukemia. The drug is present in initial stages of development and is expected to gain entry in market during the forecast period.


Apart from US, China is also making huge investments in antibody therapeutics to cope up with the market growth. The China pharmaceutical market is also expanding at large rates owing to presence of both domestic as well as international players. The growth is reliant on supportive government policies, favorable healthcare coverage rates, advancements in medical technology, and new product launches in the market. In 2020, National Medical Products Administration (NMPA) of China has announced the approval of Halpryza (rituximab injection). In addition, other key growth drivers for the market in China include the ageing trend of Chinese population, rising healthcare expenditure, and improving the public medical insurance system.


At present, therapeutic monoclonal antibodies are currently dominating the global market which is mainly attributed to large number of product approved, availability of cost effective biosimilars, and favorable reimbursement policies. However, it is estimated that bispecific antibodies will emerge as potential therapeutic option in the management of leukemia owing to their enhanced efficacy and specificity in the management of disease. Although only one bispecific antibody has entered the market, their robust pipeline suggests that several bispecific antibodies will gain entry into the market during the forecast period, thus boosting this segment.


As per our report findings, the global leukemia antibody therapeutics market is expected to surpass US$ 4 Billion by 2028. Several factors are boosting the growth of market including increasing burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in healthcare sectors. Moreover, large number of investments made in this segment has enabled pharmaceutical companies to develop more enhanced antibody therapeutics for the management of leukemia. Many pharmaceutical giants are also focusing on developing novel next generation antibody products for the treatment of leukemia in order to maintain their competitive advantage and penetrate new regional markets.

Need custom market research solution? We can help you with that too.